In this article, we will discuss Lutetium Lu 177 Dotatate (Dosage Overview). So, let’s get started.
Lutetium Lu 177 dotatate is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Important Safety Instructions
Lutetium Lu 177 dotatate is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure. Use waterproof gloves and effective radiation shielding when handling Lutetium Lu 177 dotatate. Radiopharmaceuticals, including Lutetium Lu 177 dotatate, should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
Verify pregnancy status of females of reproductive potential prior to initiating Lutetium Lu 177 dotatate.
The recommended Lutetium Lu 177 dotatate dose is 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses. Administer pre- and concomitant medications and administer Lutetium Lu 177 dotatate as recommended.